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Humans are exposed to foreign compounds like drugs, pesticides and environmental pollutants,
collectively known as xenobiotics. Being exposed in household or occupationally, xenobiotics exert
their harmful effects on human health. Metabolism an important parameter in pharmacokinetics plays
an important role in the breakdown of toxicologically active compounds into less toxic, water soluble
metabolites or bioactivation of inactive compound to toxic metabolites. A change in the metabolism
of xenobiotic being co-exposed to another chemical substance is an important cause of xenobiotic
interactions and brings considerable changes in the metabolic fate of xenobiotics. Inhibition of CYP
enzymes is the most common mechanism of xenobiotic interactions resulting in toxicity. This
inhibition can be either reversible or irreversible (suicidal inhibition) depending on the nature of
enzyme inhibitor. Reversible inhibition being the most common type of inhibition is further classified
into competitive, uncompetitive and non-competitive (mixed-type) type of inhibition. Chemical
inhibitors are of much importance in determination of in-vivo toxicities of exposed xenobiotics and in
the treatment of many poisoning cases.
The focus of experiments of this thesis work was to study inhibition of pig CYP2A19 enzymes. In this
study 96-well plate assay format was used to determine inhibition of coumarin 7-hydroxylation by
five benzothiophene derivatives and to study the effect of coumarin concentration on IC50 value of
inhibitory compounds. Benzothiophene derivatives were proved to be efficient inhibitors for
CYP2A19 in an animal (pig) model experiments. The IC50 values of 1-benzothiophen-3-carbaldehyde,
1-benzothiophene-3-ylmethylamine, 1-benzothiophen-5-carbaldeyde, 1-benzothiophene-5-
ylmethylamine and 5-choro-1-benzothio-3-carbonitrile were 2.4 (± 0.5) µM, 2.6 (± 1.0) µM, 5.3 (±
2.0) µM, 42 (± 12 µM) and 50 (± 8.0) µM respectively at 25 µM coumarin concentration. Three most
potent compounds were also checked to find out the type of inhibition. 1-benzothiophene-3-
carbaldehyde, 1-benzothiophen-3-ylmethylamine and 1-benzothiophen-5-carbaldeyde showed
competitive inhibition for CYP2A19.  Ki values for these three inhibitors were 2.21 µM, 1.73 µM and
0.91 µM respectively. The results provide initial structure-activity information about the interaction of
benzothiophene derivatives with pig CYP2A19 enzyme. The data obtained in this study can be used
for QSAR modelling for CYP 2A19 in future as the position and type of substitution affects potency
of inhibition.
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Abbreviations
ACh Acetylcholine
AChE Acetylcholine esterase
Cmax Maximum plasma concentration
CNS Central nervous system
CYP Cytochrome P450
DDI Drug-drug interaction
DMSO Dimethyl sulphoxide
EIS complex Enzyme inhibitor substrate complex
(E) Enzyme
GSTs Glutathione S-transferase
HIV Human immunodeficiency virus
(I) Inhibitor concentration (unbound)
IC50 Concentration required for 50% inhibition
Ki Inhibition constant
Km Michaelis-Menten constant for a substrate
NADPH Nicotinamide adenine dinucleotide phosphate
OPs Organophosphates
PAH Polycyclic aromatic hydrocarbons
QSAR Quantitative structure activity relationship
(S) Substrate
Sd. dev. Standard deviation
TCA Tricarboxylic acid
UDP Uridine Diphosphate
UDGPA Uridine Diphosphate Glucuronic Acid
µM Micro-molar
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1. INTRODUCTION
Foreign compounds also called xenobiotics include therapeutic drugs, plant derived or fungal
derived metabolites used in food, environmental pollutants-e.g. polycyclic aromatic
hydrocarbons, halogenated hydrocarbons, industrial mixtures, pesticides and herbicides
(Nebert & Russell, 2002). After exposure to living organisms, majority of foreign xenobiotics
undergo chemical reactions known as metabolism or biotransformation. These reactions
normally intend to convert active xenobiotics into inactive and water soluble metabolites. But
sometimes the metabolites formed get more toxic properties than parent compound and have
potency to react with tissue macromolecules and exert unwanted effects. Hepatic and extra-
hepatic enzymes are involved in such biotransformation reactions which produce metabolites
to get excreted via urine or bile (Nebbia, 2001).
Many chemicals found in food are mutagenic and carcinogenic (Lall et al. 1999). Drug-drug
and drug-food interactions are very common in systemic drug therapy. Normally these
interactions are not so intense but still can lead to mild or moderate toxicity and even
hospitalization in poisoning cases. Inhibition of drug metabolizing enzymes by other drugs is
mostly competitive and can lead to increased exposure of drug or chemical whose
metabolism is inhibited. Induction of enzymes can lead to increased metabolism and less
internal exposure of drug can lead to non-response situation (Dresser et al. 2000; Parkinson &
Ogilvie, 2008). Metabolism of many xenobiotics occurs mostly in liver but also other places
like kidney, skin, lungs and intestine are also important for metabolism of many compounds
(Miksys & Tyndale, 2011). Xenobiotic metabolism is mainly divided into two types of
reactions, namely phase I (hydrolysis, oxidation and reduction) and phase II conjugation
reactions. Xenobiotics are metabolized in one or both types of reactions to get polar, water
soluble and inactive metabolites (Martikainen, 2012).
Cytochrome P450 are a major family of enzymes involved in metabolism of drugs, chemical
compounds and carcinogens. CYP enzymes are heme containing proteins which metabolizes
toxic and pharmacologically active xenobiotics into non-toxic and inactive metabolites (Liu
et al. 2011; Miksys & Tyndale, 2011). CYP enzymes play their vital role in the breakdown of
lipophilic substances into polar and water soluble low molecular weight metabolites, which
are easily excreted through bile or urine. CYP1, CYP2 and CYP3 are major families involved
in the metabolism of many xenobiotics exposed to humans (Nebert & Russell, 2002).
Metabolic enzymes are of much importance in the breakdown of toxic substance into inactive
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metabolites. Metabolic activity of these enzymes is largely affected by interaction with
xenobiotics. Chemical compounds having closer structural similarity to substrate molecules
compete for the active site of enzymes and block the binding of substrate to enzyme. This
bonding can be strong (covalent bond) and enzyme can then completely lose its function. In
other case the bonding is not strong and as chemical inhibitor leaves the enzyme, normal
function and binding with substrate restores the enzyme (Sharma, 2012). Chemical inhibitor
technique is used when it is assessed, if CYPs metabolize different xenobiotics including
drugs (Martikainen, 2012). A change in P450 activities affects activation or inactivation of
xenobiotics (Monostory & Dvorak, 2011).  The main aim in conducting in-vitro metabolic
inhibition reaction is the qualitative and quantitative prediction of dug-drug interaction in-
vivo. Quantitative in-vitro metabolic data can be extrapolated to in-vivo situations by taking
into account suitable pharmacokinetic principles. This could be wisely used in understanding
of competitive inhibitions (Zhou & Zhou, 2009).
The aim of the present study was to find out the IC50 values of benzothiophene derivatives
against pig liver coumarin 7-hydroxylation. These results give information about effect of
substrate on inhibition and structural activity relationship with inhibition potency of chemical
compounds.
2. REVIW OF THE LITERATURE
2.1 General mechanism of toxicity of xenobiotics
Xenobiotic interactions occur when effects of chemical substances are altered by the
coadministration of another drug or chemical compound. Alteration in xenobiotic metabolism
is a common cause behind the pharmacokinetics interactions (Dresser et al. 2000). The
chemical compounds are metabolized to yield numerous metabolites; some of these produced
metabolites are active and react with body tissues to cause toxicity (Nebbia, 2001; Bozina et
al. 2009; Johnson et al. 2012). Depending upon the dose and route of exposure, all chemical
compounds can adversely affect the structure and function of tissue or organ. Concentration
and persistence of ultimate toxicant at the target site determines the intensity of the toxicity.
The ultimate toxicants can be either a parent compound to which living organisms are
exposed directly, the metabolite of the parent compound or can be reactive oxygen or
nitrogen species (ROS or RNS) generated during metabolism process in the body of living
organisms. A number of xenobiotic compounds like (strong acids, strong bases, heavy metals,
nicotine, aminoglycosides, ethylene oxide, CO) are directly toxic while many chemicals exert
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their toxicity by their metabolites. Many factors like life style, chemical nature of xenobiotic,
genetics and environment affect upcoming toxicity level (Pelkonen et al. 2008).
Chemical exposure can result in different gene expression, which could bring different
pharmacodynamics effects. A link between chemicals with different doses, tissue pathology,
site of action and level of toxicity has been an important and traditional tool in toxicity
assessment. Many cytochrome P450 enzymes have ability to metabolize various exogenous
compounds including therapeutic drugs, natural plant products and environmental toxins and
pollutants (Nebert & Russell, 2002). CYP’s are mostly involved in metabolism of chemicals
and but could also activate the pre-carcinogens metabolically (Bozina et al.  2009). As food
having different xenobiotics is digested in gastrointestinal tract, the intestinal micro-flora  are
also involved in xenobiotic metabolism and could modulate the xenobiotic –induced toxicity
by production of active or inactive metabolites (Jeong et al. 2013). Reactive and unstable
metabolites formed during xenobiotic metabolism attack DNA of cell and cause cell toxicity
and transformation (Bozina et al. 2009).  Active metabolites formed could have ability to
exert their own effects or block the action of enzyme or receptors involved in endogenous
metabolism (Johnson et al. 2012). Codeine a pharmaceutical agent is extensively metabolized
by CYP2D6 to get clinical analgesic effect, which is mainly attributed to its conversation to
morphine (active metabolite) inside the body (Salminen et al. 2010; Miksys & Tyndale,
2011). Metabolism of xenobiotics is stimulated or inhibited by other co-administered therapy
and inhibition of metabolism is quicker as compared to enzyme induction, which depends
upon the tissue concentration of inhibitor (Dresser et al. 2000; Horn, 2012).
Use of prescribed and over-the-counter pharmacological agents at the same time increases the
risk of overloading the detoxification process. This detoxification system becomes more
inefficient in poor nutritional status. Cytochrome P450 and other conjugation enzymes
present in liver, which metabolizes lipophilic xenobiotics to more water soluble metabolites
to enhance their excretion from body. Balance of these reactions determines the rate of
metabolism and elimination of xenobiotic compound and extent of intracellular damage and
toxicity from parent compound or activated metabolites (Bidlack et al. 1986). Metabolism of
foreign compounds normally leads toward successful detoxification process resulting in
inactive metabolites production, which is easy to excrete from the body. But formation of
active metabolites in metabolism, which react with body tissues and contribute increase risk
of toxicity, cancer and birth defects in newborns (Nebert & Russell, 2002).
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Figure 1. 1Potential stages in the development of toxicity after chemical exposure, 2and the
effect of metabolic inhibitor on toxicity.
Metabolic inhibitors can inhibit metabolism pathways of other chemicals and can alter the
toxicity level. Metabolism rate affects the intensity of up-coming toxicity.
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2.2 Metabolism of Xenobiotics
Biotransformation enzymes catalyze either detoxification or bio-activation reactions. Many of
xenobiotics are metabolized into active electrophilic metabolites, which interact with
nucleophilic sites on cellular macromolecules. Generally metabolism increases the xenobiotic
hydrophobicity and favors the excretion of lipophilic compounds. Metabolism prevents the
bioaccumulation of the most xenobiotics inside the body up to toxic level (Testai, 2001).
Cytochrome P450 acts on many endogenous and exogenous substrates and introduces
oxidative, reductive and peroxidative changes into chemical structure. Rate of detoxification
and sometime of metabolic activation of xenobiotics can be totally different between
individuals depending on different CYP genetics (Nebert & Russell 2002).
Figure 2. Xenobiotic metabolism pathways. More common route is functionalization
followed by conjugation reactions and then excretion. Besides some xenobiotics undergoes
conjugation directly and get excreted (modified from EOLSS).
Figure 2 shows the major (bold) and minor (blank) pathway for xenobiotic metabolism.
Majority of xenobiotics undergo functionalization reactions to form metabolites, which are
further conjugated in phase-II reaction to get excreted from the body. Mostly xenobiotics
  Xenobiotic
Functionalization
Reactions
    (Oxidation)
    (Reduction)
    (Hydrolysis)
Conjugation
     Reactions
Functionalized
metabolite
Conjugated
metabolite
      Excretion
     (Urine / bile)
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follows the same route but rarely some xenobiotics go directly to conjugation reactions and
are excreted with or without Phase-I reactions (EOLSS).
Drug metabolism is divided into two main phases: phase 1 and phase II. In phase I so called
functionalization reactions, enzymes introduce polar groups into the parent xenobiotic
compound structure. These polar groups are inherently variable reactive. This phase reactions
include oxidation, reduction and hydrolysis. After oxidation these compounds are then
conjugated to polar compounds in conjugation reactions. Conjugation or phase II metabolism
involves the introduction of hydrophilic endogenous species like glucuronic acid or sulphate
to the xenobiotic molecule (Parkinson & Ogilvie, 2008; Puccinelli et al. 2011; Martikainen
2012).
Liver is the main place for the metabolism of xenobiotics by CYPs but these metabolizing
enzymes are also found in other parts of body, .e.g. brain, kidney and intestine (Miksys &
Tyndale, 2013). Action of CYP enzymes on xenobiotics leads to biotransformation of many
xenobiotics to inactive water soluble metabolites but sometime it also produces aggressive
metabolites, which are responsible for toxicity in cell or in tissue (Daniel, 2013). Usually
xenobiotic molecules undergo functionalization reactions followed by conjugation reaction,
but sometimes the parent molecule can be conjugated without prior functionalization. This
way parent xenobiotic molecules are converted into less lipophilic metabolites by having
polar substituents. Metabolism plays an important role in the inactivation and breakdown of
drug/ xenobiotic lipophilic molecule into easily excreted metabolites. But sometimes this way
brings a big concern by metabolizing inactive parent compound into active and toxic
metabolites (Nebbia, 2001; Pelkonen et al. 2008). Metabolism of xenobiotic normally results
in successful detoxification but sometime cytochrome P450 enzymes can also generate toxic,
reactive and unstable metabolites formed during some xenobiotics metabolism which can
attack DNA of cell and cause cell toxicity and transformation ultimately leading to  cancer
and even defects in tissue structure and function (Daniel & David, 2002; Bozina et al. 2009).
2.2.1   Phase I – Functionalization
Several enzyme systems participate in phase I metabolism of xenobiotics. The major pathway
for the metabolism in phase I reactions is the monoxygenation function by cytochrome P450s
(Parkinson & Ogilvie, 2008).  Liver is the main place for the metabolism of xenobiotics while
CYP enzymes are also found in other parts of body like brain (Sharon et al. 2012). CYP-
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mediated interactions are of much importance as about 70% of prescribed drugs are
metabolized in phase-I reaction by CYP enzymes (Ramasamy et al. 2014).
2.2.1.1 Oxidation
Majority of CYP reactions are oxidation (Guengerich, 2001). Cytochrome P450 mediated
oxidation biotransformation reactions are identified in bioactivation of many xenobiotics.
CYP P450 could activate or detoxify a toxicant at the same time depending upon the type of
reaction. In some oxidation reactions the metabolites retains toxic actions of parent
compounds (Nebbia 2001).  CYP enzymes catalyze the oxidative and reductive halogenation
of many xenobiotics. Alcohol dehydrogenase, aldehyde oxidase and cytochrome P450 are
important enzymes which can catalyze the reactions and are influenced by nature of substrate
and condition of reaction (Parkinson & Ogilvie, 2008). Organophosphorus insecticides like
malathion, parathion, diazinon and fenithrothion undergo metabolic activation to develop
fully anticholinesterase activity. These derivatives are result of CYP mediated oxidative
desulphuration (Nebbia, 2001).
2.2.1.2 Reduction
Reductive reactions are carried out by either NADPH cytochrome reductase or even
cytochrome P450 under anaerobic conditions (Nebbia, 2001). However CYP do not
participate generally in biological reduction of endogenous substrates as do flavoproteins.
Nitrogen oxides and quinones are reduced by CYP and other enzymes too. Substrates which
undergo reduction reactions include N-oxides, aldehyde, ketone, alkene, sulfoxide, quinone
and nitroxides containing xenobiotics. CYP are also involved in the reduction of inorganic
molecules like Cr and SO2 (Guengerich, 2001). Many endogenous and exogenous chemicals
are also reduced inside body either enzymatically or nonenzymatically by other reducing
agents (Parkinson & Ogilvie, 2008).
2.2.1.3 Hydrolysis
Microsomal and cytosolic enzymes; esterases and amidases play vital role in the hydrolysis
of esters and amides. Many toxic compounds like OPs, pyrethroids and mycotoxins like T-2
toxins are bio-transformed into inactive metabolites in hydrolysis reactions (Nebbia, 2001).
Carboxylesterases, cholinesterases and paraoxonases are important hydrolytic enzymes
involved in the xenobiotic metabolism. Hydrolytic enzymes like carboxylesterases could
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produce toxic and tumorigenic metabolites and therefore hydrolysis is not always a
detoxification process (Parkinson & Ogilvie, 2008).
2.2.2 Phase-II reactions
Phase II or conjugation reactions include glucuronidation, sulfonation, acetylation,
methylation or conjugation with glutathione and with amino acids moities. In these reactions
the cofactors reacts with functional group present on the xenobiotic or the added during phase
I reactions. Majority of conjugation reactions increase the hydrophilicity of xenobiotics and
promote their excretion from the body. Conjugation enzymes are mainly found in the cytosol,
only UDP-glucuronosyltransferases are microsomal enzymes.  Glucuronidation, sulfonation,
acetylation and methylation are reactions with activated cofactors, while phase II reaction
involving activated xenobiotic occurs with amino acids or glutathione moiety (Parkinson &
Ogilvie, 2008).
2.2.2.1 Glucuronidation
Glucuronidation; a major pathway of xenobiotic metabolism in mammals requires mainly
cofactor UDPGA but can also use UDP-glucose, UDP-xylose and UDP-galactose. UDP-
glucuronosyltransferases located in the endoplasmic reticulum of liver and other parts of
body catalyzes the reaction. As the electron rich nucleophilic like O, N or S heteroatom are
site of glucuronidation in the atom; examples of substrate for glucuronidation are alcohols,
phenols, carboxylic acid, aliphatic amines, primary and secondary amines. Carboxylic acid
structures containing xenobiotics are glucuronidated to form acylglucoronides which can be
reactive and cause toxicity. After Glucuronidation, the xenobiotic conjugates became polar
and water soluble and are excreted from body through urine or in bile.  Inhibition of UGT´s
has been reported to involve in drug-drug interactions. Glucuronide conjugate could also go
under further metabolism stages by oxidation or even by further conjugation (Parkinson &
Ogilvie 2008).
2.2.2.2 Sulfonation
Xenobiotic and other endogenous substrate undergoing O-glucuronidation also go under
sulfonation reactions. The reaction is catalyzed by sulfotransferases enzymes family which
produces highly water soluble sulfuric acid ester. Xenobiotic conjugates are excreted mainly
in the urine. Sulfonation is supposed to be a benign metabolic pathway as compared to other
xenobiotic metabolism as it can prevent or reduce the activation of promutagens and
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procarcinogens. Sulfonation decreases the pharmacological and toxicological activity of
xenobiotics but in some cases sulfonate conjugates are chemically unstable and form potent
electrophilic species which cause toxicity inside the body. However some pharmacological
drug molecules are sulfonated and get active to exert their desired effects (Parkinson &
Ogilvie, 2008).
2.2.2.3 Methylation
Methylation a minor pathway for xenobiotic metabolism differ from other conjugation
reactions as it decreases the water solubility and covers the functional group which could go
under further metabolism by other enzymes. But N-methylation of pyridine containing
xenobiotics like nicotine makes positively charged ion that are water soluble and are easily
excreted from the body. Some inorganic compounds like arsenic undergo methylation and get
more cytotoxic and genotoxic as compared to arsenate or arsenite (Parkinson & Ogilvie,
2008).
2.2.2.4 Acetylation
 Many xenobiotics are N-acetylated after their biotransformation by hydrolysis, reduction and
oxidation. N-acetyltransferases enzymes are basically cytosolic enzymes found in the liver
and play an important role in the biotransformation of xenobiotics containing an aromatic
amine or a hydrazine group. Same like methylated conjugates, N-acetylated metabolites are
less water soluble than parent compound. N-acetyltransferases have ability to detoxify or
activate the aromatic amines which depends upon the early phase of biotransformation
(Parkinson & Ogilvie, 2008).
2.2.2.5 Amino acid conjugation
Steric hindrance around the carboxylic group and the substitution on aromatic ring or on
aliphatic ring are two factors which play an important role in ability of xenobiotic undergoing
amino acid conjugation. Endogenous amino acid substitution to xenobiotic favors the
interaction with tubular organic anion transport system of kidney and facilitates the
elimination from the body. Amino acid conjugation of carboxylic acid containing xenobiotics
leads to inactive metabolites and is a detoxification process, whereas xenobiotic containing
carboxylic acid group with glucuronidation produces potentially toxic acylglucuronides
(Parkinson & Ogilvie, 2008).
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2.2.2.6 Glutathione conjugation
Glutathione conjugation is the conjugation of xenobiotic with tripeptide glutathione (GSH)
and substrate for glutathione conjugation include electrophilic xenobiotics or xenobiotics that
could be biotransformed to electrophiles. The reaction is catalyzed by glutathione transferases
found in the cytosolic, microsomal and mitochondrial cell fractions (Parkinson & Ogilvie,
2008). Xenobiotic having hydrophobic properties, having electrophilic atom and tendency to
react with non-enzymatically with glutathione are main substrate of glutathione transferase.
Other substrate for glutathione conjugation includes reactive intermediates produced during
other biotransformation reactions, free radicals and xenobiotic with electrophilic heteroatom.
Many enzymes involved in xenobiotic metabolism have ability to produce reactive
metabolites, which are then detoxified by conjugation with glutathione. In some cases the
conjugation with glutathione produces reactive form of xenobiotic which enhances toxicity
(Parkinson & Ogilvie, 2008).
2.2.3  Human cytochrome P450 (CYP) enzyme system
The cytochromes P450 are responsible for the metabolism of many endogenous and
exogenous compounds and rank first in term of catalytic versatility to detoxify or activate a
wide range of xenobiotics to reactive metabolites (Benedetti, 2001; Ingelman-Sundberg,
2002). Cytochrome P450 is a wide heme-containing complex superfamily of enzymes and is
the major catalytic component of liver mixed function oxidase system, which catalyse the
oxidative metabolism of many xenobiotics including drugs, plant or fungal derived secondary
metabolites consumed with food, environmental pollutants, pesticides, herbicides and other
industrial compounds (Salminen et al. 2012; Emanuela et al. 2011; Van-lersel et al, 1999).
 Some CYPs are highly polymorphic enzymes regulated at multiple molecular levels and they
act as bridge between our body and environment, and their functions are linked in many ways
to initiation/prevention of carcinogenesis (Tamási et al. 2011). Humans have 57 CYP genes
and 33 pseudogenes, which are arranged into 18 families and 42 subfamilies (Nebert &
Russell, 2002). Out of 57 functional human CYP about a dozen of enzymes belonging to 1, 2
and 3 cytochrome P450 families are involved in the metabolism of many xenobiotics and
about 80% of drugs in use (Zanger & Schwab, 2013). Cytochromes P450 are divided into
families and sub families on the basis of aminoacid percentage sequence and gene nucleotide
sequence identity. Cytochrome P450 metabolizes many substrates by introducing oxidative,
peroxidative and reductive alterations (Daniel & David, 2002). CYPs are supposed to be
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present in all living species of Earth including archaebacteria, plants and in animal species
(Anzenbacher & Anzenbacherová, 2001). Cytochrome P450 being involved in the
metabolism of therapeutic drugs, are major determinants of drug half-life (Singh et al. 2011).
Major CYP involved in hepatic biotransformation of xenobiotics includes CYP1A2,
CYP2C9, CYP2C19, CYP2D6 and CYP3A4 (Figure 3) (Ramasamy et al. 2014). Metabolic
activation is of concern with CYP1A1, CYP1A2, CYP1B1, CYP2D6, CYP2E1, CYP3A4
and CYP3A5 metabolism. In some cases these enzymes are associated with increased risk of
certain types of cancer and toxic effects (Nebert & Russell, 2002).
Many members of CYP family exhibit selectivity towards specific substrate and inhibitors
(Pelkonen et al. 2008). Human liver microsomes contain more complete hepatic metabolizing
enzymes as compared to recombinant enzymes, so it is taken as more physiological to assess
CYP inhibition (Martikainen, 2012). Extra-hepatic organs like lungs, kidney and brain also
have ability to metabolize through cytochrome P450 (Ravindranath & Strobel, 2013). Many
substrates for CYP enzymes effect the metabolism of other compounds, so called drug-drug
interactions and is basis for toxicity (Dresser et al. 2000; Nebert & Russel, 2002).
Cytochrome P450 can activate or detoxify a toxicant at the same time depending upon the
reaction performed (Nebbia, 2001)
Figure 3. Cytochrome P450 abundance in human liver (modified from Galetin et al. 2008)
Major CYP's involved in the hepatic
biotransformation of xenobiotics
CYP 3A
CYP 2C
CYP 2E1
CYP 1A2
CYP2A6
CYP 2B6
CYP 2D6
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2.2.3.1 CYP1-family
The CYP1- family includes three members: CYP1A1, CYP1A2 and CYP1B1. CYP1A1 is
expressed e.g. in lung, skin, larynx and placenta and induced in liver by polycyclic aromatic
hydrocarbons. CYP1A1 has capacity to activate the compounds with carcinogenic properties
and is detected after induction of polycyclic aromatic hydrocarbons (PAH). CYP1A2 enzyme
is expressed in human liver and is about 12% of total content of CYP enzymes in human
liver. CYP1A2 metabolizes many important drugs e.g. caffeine, theophylline, clozapine and
olanzapine. CYP1A2 is also involved in the metabolism of several environmental toxins and
endogenous substances like bilirubin, melatonin and estradiol and as well as for the activation
of dietary heterocyclic amines, mycotoxins, aryl amines and tobacco specific nitrosamines.
Potent inhibitors for CYP1A2 are rofecoxib, ciprofloxacin, fluvoxamine and alpha
napthoflavone (Pelkonen et al. 2008; Martikainen, 2012). CYP1A1 and CYP1B1 are
expressed in many tissues in various concentrations and are efficient metabolizers of
compounds like polycyclic aromatic hydrocarbons.
CYP1B1 is the only member of CYP1B subfamily. CYP1B1 is involved in metabolism of
many compounds including N-heterocyclic amines, azo dyes, aryl amine, many PAHs and
other carcinogens. It has been also proposed as marker of tumorigenic potential (Pelkonen et
al. 2008). All three CYP1 enzymes are involved in detoxification or activation of many
environmental carcinogens (Nebert & Russell, 2002). Ciprofloxacin, rofecoxib used as
therapeutic drugs oral contraceptives have shown significant inhibition of CYP1A2 mediated
metabolism in humans (Pelkonen et al. 2008). Inhibitors for porcine CYP1A subfamily
include ellipticine and alpha-naphthoflavone (Puccinelli et al. 2011)
2.2.3.2 CYP2-family
CYP2-family involved in mammalian drug metabolism is one of largest and most diverse
family in CYP enzymes (Martikainen, 2012). Many therapeutic drugs (more than 100) are
metabolized into active and inactive metabolites by CYP2 family. Different CYP2 families
are involved greatly in the metabolism of anti-depressants, antipsychotics, drug of abuse like
ethanol and amphetamine, endogenous neurochemicals like dopamine and serotonin (Sharon
et al. 2012). CYP2A6 mediates the oxidative metabolism of many xenobiotic with
procarcinogenic activity targeting human liver (Raunio et al. 1998). Human CYP2A6 is the
key enzyme in the elimination of nicotine and it is known to be involved in bio-activation of
some toxicologically important substances such as aflatoxin and nitrosamines and CYP2B6 is
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of considerable importance due to bio-activation of many procarcinogens (Pelkonen et al.
2008). Some natural and herbal products are metabolized by CYP2C9, which could lead to
formation of toxic metabolites. However it is also involved the metabolism of anticoagulant
warfarin and in many endogenous metabolisms of steroids, melatonin and retinoids. Mostly
weak acids are substrate of CYP2C9, but it could also metabolize many neutral or highly
lipophilic compounds. Irreversible inhibitors for CYP2C9 include tienilic acid, suprofen and
silybin which potentially give rises to adverse drug interactions (Zhou et al. 2009). CYP2C9
and CYP2C19 also metabolize centrally acting antidepressants, anxiolytics and
anticonvulsants. Inhibitors for these enzymes will inhibit the metabolism process of ingested
drugs and will lead to increased plasma concentration of these active xenobiotics. This
increased plasma concentration will result in adverse reaction and different toxicities
(Ramasamy et al. 2014). Many drugs acting on central nervous system are metabolized by
members of CYP2 family into active or inactive metabolites (Miksys & Tyndale, 2013).
Human CYP2C8, CYP2C9, CYP2C18 and CYP2C19 in various amount metabolizes more
than half of prescribed medicines and some endogenous steroids. Other members of this
family have important role in drug metabolism and synthesis of vasodilator by vascular
endothelium (Nebert & Russell, 2002). Androgens and diethyldithiocarbamate are well
known porcine CYP2A inhibitor. Sulfaphenazole, ticlopidine and beta-naphthoflavone are
porcine CYP2C inhibitors. Quinine, quinidine and phenobarbital have porcine CYP2D
inhibition properties (Puccinelli et al. 2011).
2.2.3.3 CYP3-family
CYP3A4, CYP3A5, CYP3A7 and CYP3A43 are four isoforms grouped in CYP3A subfamily
of enzymes. CYP3A4 is found in largest amount of CYP in the liver, while CYP3A5 is found
in minor quantity expressed in lungs. CYP3A7 is majorly present in human fetal liver.
CYP3A4 is majorly expressed in human liver where it accounts for about 35% of total liver
CYP enzyme content. Being responsible for about 50% of known drugs metabolism,
CYP3A4 is the most abundant human hepatic CYP isoform (Dresser et al. 2000; Salminen et
al. 2011). CYP3A4 inhibition is related to many of drugs interactions inside the body.
CYP3A4 with large active site favors the binding of multiple substrates and could be cause of
atypical kinetics. Antiarrhythmic agents, anxiolytics, HIV protease inhibitors, lipid-lowering
agents and opioids are mostly substrate for CYP3A4 (Parkinson & Ogilvie, 2008). Ligand
competition with CYP3A4 originates many drug-drug interactions (Dresser et al. 2000;
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Shinkyo & Guengerich, 2011). CYP3A4 inhibitor such as midazolam probably binds
covalently to CYP apoprotein and finally inactivates the enzyme. Other CYP3A4 inactivators
like erythromycin and nelfinavir can bind with heme part of CYP and consequently
inactivates the enzyme (Zhou & Zhou, 2009). Many anticancer drugs can induce and inhibit
CYP3A4 in liver and extrahepatic tissues (Kivistö et al. 1995). CYP3A interactions favor the
formation of drug reactive metabolite–CYP3A to initiate toxicity (Zhou & Zhou, 2009).
Inhibition of CYP3A4 mediated drug metabolism is thought to be major cause of drug
interactions. CYP3A4 interactions could lead to adverse clinical consequences of
rhabdomyolysis, symptomatic hypotension, excessive sedation and ataxia. Many inhibitors of
CYP3A4 are of clinical relevance and can be used to achieve beneficial therapeutic goals;
cost saving or enhanced efficacy of other xenobiotics (Dresser et al. 2000). Porcine CYP3A
inhibitors include ketoconazole, triacetyloleandomycin and tiamulin (Puccinelli et al. 2011)
2.3 Inhibition of xenobiotic metabolism
Acute or chronic exposure to certain xenobiotics may cause adaptive changes in overall
metabolism capacity of living organisms. The resulting decrease in metabolic rate of
endogenous or exogenous substrate is referred as inhibition (Nebbia, 2001). Enzymes are
protein molecules acting as catalyst in reactions (Sharma, 2012). Generally inhibition brings
decrease in enzyme activity (Martikainen, 2012). Enzyme inhibition is phenomenon of
enzyme-substrate reaction influenced by presence of any organic or inorganic chemical, any
metal or biosynthetic compound which interacts with active site of enzymes by covalent or
non-covalent bonds (Sharma, 2012). Inhibitions of CYP enzymes plays key role in the drug-
drug interactions and have been a main cause in the removal of many drugs from market.
Knowledge about CYP inhibition gives information about potential drug-drug and other
exposed xenobiotics interactions (Turpeinen et al. 2006). Metabolic interactions are mainly
linked  to  CYP  enzymes  and  are  result  of  inhibition  or  induction  of  CYP  enzymes
(Martikainen, 2012). Many mechanisms could lead towards enzyme inhibition like decreased
protein synthesis or accelerated protein breakdown, reversible or irreversible interactions and
competition between two xenobiotic toward same binding site (Nebbia, 2001). Inhibition of
metabolism can lead to increased concentration of parent compound in the circulation and
decreased elimination of parent compound (Pelkonen et al. 2008). Inhibition of CYP enzymes
is the most common mechanism which leads finally to drug-drug interactions (Fontana et al.
2005; Kalgutkar et al. 2007). Broadly inhibitory drug-drug interactions are categorized into
reversible and irreversible inhibition. Irreversible inhibition is also known as mechanism
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based inhibition or suicide inhibition (Ring et al. 2014; Zhou & Zhou, 2009; Kalgutkar et al.
2007). Competitive inhibition is the most common type of reversible enzyme inhibition
(Martikainen, 2012). Changes in intracellular metabolism can alter enzyme level and also the
availability of their cofactors; NADPH, UDPGA and GSH.  Diets with protein or high sugar
content affect the component enzyme, cytochrome P450 and cytochrome P450 reductase
towards a variety of xenobiotics (Bidlack et al. 1986).
2.3.1 Reversible inhibition
Reversible inhibition is the most common in all enzyme inhibition and is further subdivided
into competitive, uncompetitive and mixed type inhibition (Ring at al. 2014; Martikainen,
2012; Pelkonen et al. 2008). Reversible inhibition develops as a result of non-covalent
interaction between inhibitory compound and amino acid residue in the active site of enzyme
involved. Bonds formed are weak as compared to covalent bonds of irreversible inhibition.
As bonds are weak so they don’t inactivate enzyme for longer time or completely (Ring et al.
2014).
(http://www.wiley.com/college/boyer/0470003790/animations/enzyme_inhibition/enzyme_inhibition.htm)
Figure 4. Schematic representation of “Enzyme-substrate complex (a) and three types (b,c,d) of
reversible inhibition”.
E = Enzyme
S = Substrate
I = Inhibitor
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Reversible inhibitors have three mechanisms by which perpetrator interact with enzyme
including competitive, uncompetitive and mixed type (noncompetitive) inhibition. Potential
for a xenobiotic to be a clinically significant reversible inhibitor is the equilibrium
dissociation constant (Ki) for enzyme-inhibitor complex (Ring et al. 2014; Sharma, 2012).
Omeprazole and diazepam both are metabolized by CYP2C19. If both are administered
together, omeprazole competitively inhibits the metabolism of diazepam and increase its
plasma half-life. Inhibition of diazepam is linked with the omeprazole competition for
inhibition by CYP2C19. This inhibition interaction between these two drugs is only seen in
population having CYP2C19 (Parkinson & Ogilvie, 2008).
2.3.1.1 Competitive inhibition
The competitive inhibition usually occurs between the substrates for same enzyme (Miners &
Birkett, 1998; Sharma, 2012). Principally in the competitive inhibition there is a mutually
exclusive binding of either the substrate or the inhibitor at a single active or binding site of a
drug metabolizing enzyme. Thus two different drugs/ chemical compounds compete with
each other for binding to single active site (Ring et al. 2014). In the competitive inhibition the
substrate and the inhibitor compete for the same active site of enzyme, the inhibitor replaces
the substrate and get bind to active site of enzyme.  As seen in figure 5, substrate
concentration decreases the inhibition by inhibitors in competitive inhibition reactions and
IC50 values increases by increasing substrate concentration (fig. 5) (Ramasamy et al. 2014).
Figure 5. The effect of substrate concentration on the IC50-value of competitive inhibitors.
The inhibitor binds to the active site of the free enzyme reversibly. Enzyme inhibitor complex
formed prevents binding of the substrate as active site is already been taken by inhibitor.
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Competitive inhibitors reduce the availability of free enzymes for substrate. Competitive
inhibitors do not make strong covalent bonds with active site of enzymes. Once the inhibitor
leaves the enzyme, enzymes work normally in binding and catalytic reactions with substrates
(Sharma, 2012). Products of enzymatic reactions also behave as reversible inhibitors of
enzymes (Sharma, 2012).
Isoniazid a therapeutic drug at clinically concentration reversibly inhibits CYP2C19 and
CYP3A4 activities and inactivates CYP1A2 and CYP2A6 in human liver microsomes. Co-
administration of isoniazid with other substrate of CYP2C19 and CYP3A4 could lead to
inhibition of their metabolism and may result in toxicity reactions (Wen et al, 2002).
2.3.1.2 Un-competitive inhibition
Uncompetitive inhibitors have no similarity to the substrate. It’s a rare type of inhibition and
inhibitor could be a reaction product. Inhibitor does not bind to the free enzyme but with
enzyme-substrate complex that exposes the inhibitor binding site (Martikainen, 2012).
Although  it  binds  away  from  the  active  site,  but  still  it  causes  structural  distortion  of  the
active site and allosteric sites which finally brings inactivation to catalysis function. The
resultant EIS-complex formed is catalytically inactive (Sharma 2012).
Figure 6. The effect of substrate concentration on the IC50-value of uncompetitive inhibitors.
 As the figure (6) shows, inhibition increases until substrate concentration increases up to
saturation level (Martikainen, 2012). In uncompetitive inhibition Vmax decreases and Km of
substrate increases. This type of inhibition could be seen in multi substrate enzymes, where
inhibitor competes only for one substrate having structural similarity but is uncompetitive for
other substrates. Dialysis could be beneficial in reversal of inhibition as by increasing
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substrate concentration does not affect the inhibition process. Examples of commonly
uncompetitive inhibition include; inhibitions of lactate dehydrogenase by oxalate, inhibition
of heme synthetase by heavy metal ion e.g., lead. These inhibitions require treatment with
reducing agents and/ or dialysis (Sharma, 2012).
2.3.1.3 Non-competitive inhibition
Non-competitive inhibition is a form of mixed type inhibition reactions (Martikainen, 2012).
These types of inhibitors have also no structural  similarity to substrate but in this way they
have ability to bind both to free enzyme and enzyme-substrate complex as well. The presence
of substrate has no influence on the ability of non-competitive inhibitor to bind an enzyme
and vice versa.
Fig 7. The effect of substrate concentration on the IC50-value of non-competitive inhibitors.
As shown in figure 7 by increase or decrease in the substrate concentration does not affect the
inhibition reaction and have no influence on reversibility of inhibition reaction and there is a
reduced metabolic rate regardless of substrate concentration (Martikainen, 2012). Although
the inhibitor binds away from active site but its changes the conformation of enzyme by
affecting the nature of catalytic groups on active site and then reduces its catalytic
performance. EI and ESI complexes formed are non-productive and increasing substrate
concentration is ineffective.
Many poisons including cyanide and azide are common examples of noncompetitive
inhibitors (Sharma, 2012).
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                      2.3.2 Irreversible inhibition
The irreversible inhibitors bind covalently to enzyme and have no structural relationship to
substrate (Sharma, 2012). Irreversible inhibition also known as mechanism based inhibition
results from either strong covalent bond formation between heme and protein of CYP and
reactive metabolites or metabolite intermediate complexes are formed (Van-lersel et al.
1999). Mechanism based CYP inactivation usually involves bioactivation of xenobiotic to
reactive metabolite, which in some cases triggers auto immune response and can lead to
toxicity. Irreversible inhibition have more chances to elicit drug-drug interactions as the
inactivated CYP enzyme has to be replaced by newly synthesized protein (Kalgutkar et al.
2007; Kamel & Harriman, 2013). Mechanism-based inhibition of CYPs is characterized by
NADPH, time and concentration dependent enzyme inactivation and by substrate protection.
As CYPs have important role in metabolism, inactivation of CYPs leads toward clinical drug-
drug interactions and adverse drug reactions with final toxicity outcome (Zhou & Zhou,
2009).  Irreversible inhibition is usually long lasting as it could be overcome by resynthesis of
enzyme. Time, concentration and NADPH dependent enzyme inactivation are important
factors in irreversible inhibition. Suicide inhibition is an irreversible inhibition in which
metabolic product inactivates the enzyme totally (Pelkonen et al. 2008). Kinetically
irreversibly inhibitors decrease the concentration of active enzymes with ultimate reduction
in ES complex formation and decrease in reaction rate of inactivated enzyme. Remaining
unbound enzymes molecules are normally functional and have free active site for substrate
binding (Sharma, 2012).  Many drugs are irreversible inhibitor of CYP enzymes like
CYP3A4. These bind to CYP3A4 and inactivate the enzyme irreversibly. In the data
extrapolation from in-vitro to in-vivo more factors should be taken into account for
mechanism based CYP inhibition (Zhou & Zhou 2009).
2.4 Inhibition interactions, toxicity and clinical use
Drugs, pesticides and environmental pollutants have ability of enzyme inhibition (Nebbia,
2001).  Inhibition  or  induction  of  CYP  enzymes  give  rises  to  metabolic  interactions  and
toxicities (Martikainen, 2012). Inhibition of metabolism of a drug results in increase in
exposure to drug in patients, probably outside the therapeutic window and increases the
possibilities of adverse drug reactions in patients (Ring et al. 2014). Generally it is suggested
that even small changes in pharmacokinetics of xenobiotics could bring alterations in efficacy
and  toxicity  profile  (Kivistö  et  al.  1995).   Inhibition  of  CYP  enzymes  results  in  increased
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plasma concentration of parent drug through decreased drug metabolism, which results in
increased risk of adverse effects or toxicity from parent drug molecules (Ramasamy et al.
2014). In nature animals and plants have and are exposed to many poisons as secondary
metabolites, peptides and proteins that behave as enzyme inhibitors. Reversible interaction of
a xenobiotic or drug with the enzyme results in inhibition of drug metabolizing enzyme,
which decreases the metabolism of another drug and is the major cause of clinically
significant drug-drug interactions (Ring et al. 2014).  Ethanol consumption is widespread and
has effect on the absorption, plasma protein binding, blood flow and distribution of other
xenobiotics  as  well  as  on  phase  I  and  phase  II  metabolism  of  xenobiotics.  Inhibition  of
CYP2E1 function is caused by acute consumption of ethanol via competitive inhibition
(Yang et al. 1992). Enzyme inhibition is of practical importance in the prediction of drug-
drug interactions. Sometimes enzyme inhibition technique is used to inhibit the formation of
toxic metabolites of an exposed xenobiotic in poisoning treatment (Nebbia, 2001).
Methanol also known as wood alcohol is widely present in the cleaning solutions, stains, dyes
and other industrial and household chemicals. Absorption of methanol occurs through oral,
dermal or inhalation routes mostly in accidental or suicidal attempts. The lethal dose of pure
methanol is about 1-2 mL/kg. Methanol toxicity may lead to permanent blindness and death.
Methanol is metabolized in liver by alcoholdehydrogenase phase-I reaction. The metabolites
formed are more toxic then the parent molecule and exert severe toxicity in exposed
population. Methanol is metabolized to formaldehyde in the presence of
alcoholdehydrogenase enzyme. Then formaldehyde is oxidized to formic acid by
formaldehyde dehydrogenase. Formed formic acid is the toxic metabolite of the methanol and
is very persistent inside the body with half-life of about 20 hours. Another industrial solvent
ethylene glycol is also used as coolant and anti-freeze exert toxicity inside the body after
accidental or suicidal ingestion. After metabolism by hepatic enzymes more active
metabolites; glyoxylic acid and oxalic acid are produced. These metabolites accumulation
leads toward fatal acidosis and renal failure. This metabolism makes more complex toxicity
rather than parent ethylene glycol. Inhibition of further metabolism of ethylene glycol and
elimination of both parent and metabolites molecules are important steps in therapy. The use
of antidote like high concentration of ethanol saturates the alcohol dehydrogenase and
prevents the metabolism of ethylene glycol. Fomepizole with less adverse effects is
alternative to ethanol is successfully used inhibitor metabolizes in a predictable manner and is
safe to use in methanol and ethylene glycol poisonings and inhibits the formation and
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accumulation of formate (Brent, 200; Jammalamadaka & Raissi, 2010). Fomepizole or 4-
methylpyrazole acts as potent competitive inhibitor of alcohol dehydrogenase inhibits the
initial steps in the convertion of methanol to toxic metabolites. 4-methylpyrazole is used
extensively in methanol and ethylene glycol poisoning due to its longer duration of action and
lesser adverse effects. It can be seen in data that ethanol also inhibits the metabolism of
fomepizole in the body and thereby increases the therapeutic blood levels of 4-
methylpyrazole. Normally self-poisoned or accidental have ingested ethanol with methanol or
ethylene glycol so this mutual interaction could have good clinical result (Jacobsen et al.
1996). Methanol poisoning without treatment causes serious intoxications complicated by
visual impairment, coma, metabolic acidosis, respiratory and circulatory insufficiency and
finally death (De Brabander et al. 2005).
Steroid hormones are biologically active compounds play a vital role in the physiological
process by endocrine signaling pathways. Xenobiotic exposure can change endocrine
function either directly as hormone agonist/antagonist or indirectly by altering hormone
metabolism rate. Xenobiotics by modulating P450 expressions have effects on both foreign
chemicals and on endogenous steroid hormones. This disturbance in hormone metabolism
leads towards imbalance in sexual and reproductive development/function, glucose, lipid and
salt/water balance inside body (Monostory & Dvorak, 2011). Teastosterone and its
metabolically active form dihydrotestosterone are vital for male reproductive system and
spermatogenesis. Testosterone is biosynthesized in the leydig cells of testis from cholesterol.
Many industrial chemicals like phthalates, bisphenol A, benzophenone and pestcides/biocides
acts as antiandrogens, because they inhibit one or more enzymes involved for testosterone
biosynthesis and metabolic activation. Thus inhibition in testosterone biosynthesis and
activation leads to reproductive and developmental toxicity (Ye et al. 2011).
Organophosphate compounds used as insecticides are extremely useful in agricultural pest
control  all  over  the  world,  but  their  extensive  use  targeted  many  other  species  including
humans. Organophosphate pesticides inhibit the acetylcholinesterase enzyme from breaking
down acetylcholine, thereby increasing level and duration of action of the acetylcholine. The
inhibition could be reversible or irreversible (Sultatos, 1994). Inhibition of AChE leads to
accumulation of ACh in the synaptic cleft and results in impeded neurotransmission.
Irreversible inhibitors of AChE may lead to muscular paralysis, convulsions, bronchial
constriction, and death by asphyxiation (Harper et al. 2009).
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Cholesterol is present in high concentration in liver. With low solubility and equilibrium with
bound forms, still high concentration is of potential risk factor in human beings. Cholesterol
is metabolized (hydroxylated) by CYP3A4 in an in-vivo reaction. Other than as a substrate
for CYP3A4, cholesterol showed non-competitive inhibition toward three oxidation reactions
catalyzed by CYP3A4. Increased cholesterol level have ability to inhibit the CYP3A4 activity
in hepatocytes, resulting in conclusion that basal and elevated levels of cholesterol in human
liver could affect metabolism of clinical drugs and other compounds by CYP3A4 (Shinkyo &
Guengerich , 2011).
Dietary influences on xenobiotic metabolism could alter the therapeutic effects of drugs and
toxicity or carcinogenicity of environmental chemicals (Yang et al. 1992). Flavonoids
naturally present in fruits and vegetables with enzyme modulating activities results in
decreased carcinogenicity of xenobiotics. The flavonoids have effects on CYP, which are
involved in activation of procarcinogens. Flavonoids inhibit competitively or irreversibly
CYP enzymes including CYP1A1, 1A2, 2E1 and 3A4. Flavonoids also activate phase II
detoxifying enzyme; such as UDP-glucuronyl transferase, glutathione S-transferase and
quinone reductase which play important role in detoxification of carcinogens. These
flavonoids could have interactions with chemotherapeutic drugs through induction or
inhibition of their metabolism (Moon et al. 2006).
Chemical inhibitors are of importance because of their widespread availability, stability and
cost effectiveness (Liu et al. 2011). Inhibitors are used to find out the in-vivo toxicity
outcomes of exposed xenobiotics by inhibition of their metabolism. Chemical inhibitors have
been used as important tool to determine the enzyme involvement in the in-vitro P450
mediated biotransformation of xenobiotics as well as of endogenous compounds (Nebbia,
2001). Co-administration of CYP3A4 irreversible inhibitors are used to get beneficial drug
interaction in some clinical treatments. Mechanism based CYP3A4 inhibitors are used with
cyclosporine. This administration may allow reduction of the dosage and cost of
immunosuppressant.  In HIV/AIDS patents co-administration of inhibitors allows reduction
of dosage and cost of immunosuppressant. Ritonavir an antiviral is used as booster in
protease inhibitors therapy to inhibit CYP3A4 that normally metabolizes protease inhibitors
(Zhou & Zhou, 2009).
Methotrexate an anticancer drug is the competitive inhibitor of dihydrofolate reductase. It is
used as antimetabolite chemotherapy in pediatric leukemia. Methotrexate resembles
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structurally to dihydrofolate and behaves as competitive inhibitor of dihydrofolate reductase.
Methotrexate hinders the availability of tetrahydrofolate being important for anabolic
process. This finally leads to the decreased synthesis of purine nucleotides for DNA
replication. Neurotoxins are natural inhibitors, which are toxic in nature but are of therapeutic
importance at low doses. Glycoalkaloids present in many plants (potato, tomato, and
eggplant) inhibits acetylcholinesterase results in increase acetylcholine concentration,
muscular paralysis and then death in severe conditions. Many invertebrates and vertebrates
venoms contain protein and peptide enzyme inhibitors for plasmin, renin and angiotensin
converting enzymes. Reversible competitive inhibitors of acetylcholinesterase; physostigmine
and neostigmine are used in the treatment of myasthenia gravis and in anesthesia. Among
pesticides, carbamates are commonly exposed reversible acetylcholinesterase inhibitors
(Sharma, 2012).
Although xenobiotic-metabolism inhibition interactions are generally having negative
adverse effects on health and are mostly to be avoided but they are also been in use to achieve
beneficial therapeutic effects against diseases and poisoning treatment (Dresser et al. 2000,
Sharma, 2012).
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3. EXPERIMENTAL PART
Pigs are getting widely used as test animals in pharmacological and toxicological assessment
of new xenobiotic substances and compounds. Many studies suggest to use pig or mini pig as
a new animal model for humans with many advantages. Because of anatomical, physiological
and biochemical similarity to humans, pigs are animals of choice for testing the different
compounds to which humans are exposed. Similarity towards humans in heart, nasal cavity,
liver, kidney, brain, reproductive and gastrointestinal system favors pigs more for in vitro and
in vivo experiments rather than other animals (Puccinelli et at. 2011).
As the pigs are largely used in medical studies and research so they can also be a useful
model to study the biotransformation of xenobiotics in humans (Matal et al. 2009). Pig CYP
enzymes get importance to study as pig liver and hepatocytes to use as against the shortage of
human organs in transplantation techniques and treatments. Pigs and minipigs could be good
model species for pharmacology and toxicology studies with no need to induce
biotransformation enzymes (Liu et al. 2011).
Pigs have been recognized as a model for human diseases like cardiovascular diseases
(atherosclerosis), metabolic diseases (hypercholesterolemia) and neural diseases (Parkinson’s
and Alzheimer’s). In the non-rodent species the generation of transgenic animals and
xenotransplantation is well known in pigs (Puccinelli et at. 2011).
 The in vitro metabolic inhibition studies gives information to predict the drug-drug
interactions qualitatively and quantitatively inside the body. This quantitative in vitro
metabolic data could be extrapolated to in vivo situations for competitive inhibition by help
of appropriate pharmacokinetic principles (Zhou Z & Zhou S 2009).
Coumarin a plant derived natural product belongs to polyphenolic compounds and is well
known for its pharmacological properties like anti-inflammatory, antibacterial, anti-viral,
antifungal and antioxidant properties (Venuqopala et al 2013). Coumarin being a plant
alkaloid being well known for its immunomodulatory and antitumour activity is metabolized
mainly to 7-hydroxylated form by CYP2A6 in humans (Pelkonen et al. 2008), CYP2A5 in
mice and in pigs by CYP2A19 (Kinonen et al. 1995; Skaanild & Friis, 2005; Puccinelli et al.
2011). Coumarin 7-hydroxylation is the most utilized activity marker for CYP2A6 in humans
(Liu et al. 2011) and in humans liver coumarin 7-hydroxylation activity level is higher as
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compared to pigs (Puccinelli et al. 2011). CYP2A6 is an important isoform of CYP involved
in precarcinogen activation and oxidation of many important drugs inside human body.  Five
different benzothiophene derivatives were tested as an inhibitor against pig liver microsomal
coumarin 7-hydroxylation under the presence of NADPH and oxygen. Coumarin 7-
hydroxylase activity has been identified in pigs as well as in conventional and minipigs (Liu
et al. 2010). The method is based on the detection and measurement of fluorescence emitted
by 7-hydroxy coumarin in alkaline condition (Fig. 8) (Aitio, 1978; Rahnasto et al. 2011).
(CYP2A19 of Pig Microsomes)
O O O OOH
Coumarin 7-Hydroxycoumarin
     Florescing Product
NADPH
NADP+
+
Figure 8. Oxidation of coumarin to 7-hydroxycoumarin.
Reaction occurs in the presence of CYP2A19 of Pig liver Microsomes and NADPH in Tris
HCL buffer pH 7.4. CYP2A19 inhibiting compound decreases the catalytic efficiency and
therefore fluorescence is reduced.
3.1 Aims of the study
In the experimental part, I studied the inhibition of pig liver coumarin 7-hydroxylation with
following benzothiophene derivatives:
x 1-Benzothiophene -3-carbaldehyde
x 1-Benzothiophene-3-ylmethylamine
x 1-Benzothiophene-5-ylmethylamine
x 1-Benzothiophene-5-carbaldehyde
x 5-chloro-1-benzothiophene-3-ylmehylamine
Fluorescent Product
Fluorescence
Muhammad Umer Naeem
The role of metabolic inhibition-interactions on toxicity
26
The aim was to
1. determine the IC50 values of above listed benzothiophene derivative against pig liver
coumarin 7-hydroxylation
2. study the effect of coumarin concentration on the IC50 value of these compounds.
These experiments give us information about inhibition structure-activity relationship against
pig coumarin 7-hydroxylation via CYP2A19.
Table 1. Chemical structures of inhibitory compounds
Inhibitory compounds     Structure
1-benzothiophen-3-
carbaldehyde
S
O
1-benzothiophene-3-
ylmethylamine
S
NH2
1-benzothiophen-5-
carbaldehyde
S
O
1-benzothiophen-5-
ylmethylamine
S
NH2
5-chloro-1-benzothio-3-
carbonitrile
S
Cl
N
Muhammad Umer Naeem
The role of metabolic inhibition-interactions on toxicity
27
3.2 General Experimental Procedure
3.2.1 Materials
3.2.1.1 Chemicals
x 1 M Tris-HCL buffer pH 7.4, Ultra-pure by MP Biomedicals France.
x 50 mM Tris-HCL by MP Biomedicals France
x 30 % Trichloroacetic acid (TCA) by Sigma Aldrich Germany
x 10 mM Coumarin/ 1mM coumarin/ 25 µM  coumarin by Sigma Aldich Germany
x 10 mM 7-hydroxycoumarin standards by Sigma Aldrich Germany
x Pig liver microsomes
x 100% DMSO from J.T.Baker, Holland.
x 10 mM inhibitor stock solution of compound in 100 % DMSO
x NADPH regenerating system (Prepared by department laboratory technician)
x Water (H2O) was purified using MAXIMA USF ELGA instrument at 18.2 MǷ.
x 100 % ethanol was obtained from Altia Oy Finland.
3.2.1.2 Biological material
Microsomal fractions were prepared from three different pigs’ livers by differential
centrifugation as described in Lang and Nebert (1981), by the department’s laboratory
technician on the 4.06.2007. They were collected from the fridge stored at -800C for the
assays. The total protein concentration (mg/ml) of microsomal preparations was determined
with the bicinchoninic acid (BCA) protein assay kit.
3.2.2 Inhibition assay of Coumarin 7-hydroxylation
3.2.2.1 IC50 value determination
Assay of 7-hydroxylation activity is based on fluorescence activity emitted by 7-
hydroxycoumarin in alkaline condition observed in spectrofluorometer.  96-well plate format
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was used for inhibition analysis. Different concentrations of inhibitors and standard (7-
hydroxycoumarin) were run in duplicate manner in 96 well plates.
96 well  plate with parafilm on the base was kept on the ice in the start  of the experiments.
Chemicals listed table 2 were pipetted in the wells of plate. Final concentration volume in
(table 2) reaction well of 100 µl of incubation volume contained 5 µl of 20 % DMSO , 5µl of
1 M Tris-HCL, 1 µl of 25 µM coumarin, 5 µl of diluted pig liver microsomes, 59 µl of water
and 25 µl of NADPH regeneration system was added in order to start the reaction.
Table 2. Experimental protocol to determine IC50-value for 1-benzothiophene-3-
carboxylaldehyde.
Reagents Reaction Blank Blank
compound
Inhibition by a
compound
1 M Tris-HCl
pH 7.4       5 µl      5 µl      5 µl       5 µl
25 µM coumarin       1 µl       1 µl        ----       1 µl
1/20 pig liver
microsomes       5 µl       ----       5 µl       5 µl
    Water      59 µl  59 µl + 5 µl  59 µl + 1 µl        59 µl
Inhibitory
compound of
different conc.       ----        ----        5 µl       5 µl
20% DMSO    5 µl      5 µl         ----       ----
NADPH
regenerating
system
    25 µl     25 µl      25 µl       25 µl
To check the inhibition potency of 5 µl inhibitory compounds of different concentrations (0-
100 µM) was pipetted to above listed incubation mixture. The plate was pre warmed for 5
min at 37oC in the incubator. Then the reaction was started by pipetting 25 µl of NADPH
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regenerating system. After 20 minutes incubation at 37 oC the reaction was stopped by adding
10 µl of 30 % TCA to all wells of reaction, blank and inhibition. Two different pairs of blank
wells were prepared by omitting coumarin, DMSO or inhibitory compound. 100 µl of 7-
hydroxycoumarin standards (0, 0.010 µM, 0.025 µM, 0.050 µM, 0.100 µM, 0.250 µM, 1.0
µM) and 10 µl of 30 % TCA were pipetted into duplicate pattern in different wells.
Just before the measurement 140 µl of 1.6 M glycine pH 10.4 buffer was added to all wells.
Fluorescence was measured with VICTOR2TM plate counter fluorescence spectrophotometer
(Perkin Elmer Life Sciences, Wallac, Turku, Finland). Coumarin program with excitation 355
nm and emission 450 nm wavelengths was used.
3.2.2.2 Effect of coumarin concentration (substrate) on IC50 value
To check the effect of coumarin concentration on the IC50 value of inhibitory compounds, the
above described procedure was done at (3.125 µM, 6.25 µM, 12.5 µM, 25 µM, 50 µM and
100 µM) coumarin concentrations. Fluorescence activity was measured for each sample and
results were plotted to see the effect of increasing substrate concentration on the IC50 values
of chemical inhibitors.
3.2.3 Data analysis.
IC50 of all five benzothiophene derivatives were calculated for three different pig liver
microsomes catalyzed coumarin 7-hydroxylation using equation (1) and  Microsoft excel
2007 (figure 4).
(1)                             Vi/Vo = 1/ (1+I/IC50))
Where
   Vi represents the reaction rate with inhibitor. Vo represents the reaction rate without
inhibitor, [I] is the concentration of inhibitor and IC50 is the concentration of the inhibitor
producing 50% inhibition.
Mean IC50 and standard deviation of three different pig coumarin 7-hydroxylation inhibition
experiments were calculated.
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Ki values of three most potent inhibitory compounds were calculated by equation (Cheng and
Prusoff 1973).
(2) Ki= IC50 / (1+[S/Km]) + E/2
Where IC50 is the concentration of the inhibitor producing a 50% inhibition, Ki is the
equilibrium dissociation constant of the inhibitor. (S) is the substrate concentration used and
Km  is  the  Michaelis  constant  of  the  coumarin  (24  µM)  for  pig  liver  coumarin  7-
hydroxylation (Pig as a test animal in toxicity studies) Faculty of Health Sciences, School of
Pharmacy, Master’s thesis 2010.
When S = 0 and E is in nM,
then
Ki ؄ IC50
Figure.9 A dose-response curve for model and experimental values of inhibition of pig liver
coumarin 7-hydroxylation by 1-benzothiophen-3-carbaldeyde. Blue and red series represent
model and experimental values, respectively.
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3.3 Results
3.3.1 IC50-values of inhibitors.
The inhibitory potency of benzothiophene derivatives were tested towards pig coumarin 7-
hydroxylase activity in a concentration-response relationship experiment (Table 3, fig. 10-
14). All five compounds with different concentrations were tested in concentration- response
manner  with  three  different  pig  liver  microsomes.  Among  all  tested  compounds  the  5-
choloro-1-benzothio-3-carbonitrile was the least potent with IC50 value  50  µM.  While  the
most potent compound found to be thianaphthene-3-carboxaldehyde IC50 value 2.4 µM.
Table 3. IC50 values of Benzothiophene derivatives towards pig liver microsomal coumarin
7-hydroxylation.
Inhibitory
Compounds
  Pig # 4
(IC50 µM)
  Pig # 10
(IC50 µM)
  Pig # 11
(IC50 µM)
   Mean
(IC50 µM)
    Std.
Deviation
1-benzothiophen-3-
carbaldeyde
   1.85     2.57     2.74     2.4    ± 0.5
1-benzothiophene-3-
ylmethylamine
   3.25     1.49     3.14     2.6 ± 1.0
1-benzothiophen-5-
carbaldeyde
   5.05     7.30    3.38     5.3 ± 2.0
1-benzothiophene-5-
ylmethylamine
   28.83    51.90     44.43      42    ± 12
5-choro-1-benzothio-
3-carbonitrile
  44.07     59.01     45.85      50 ± 8.0
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Figure 10. Inhibition of pig liver coumarin 7-hydroxylation by 1-benzothiopene-3-
caroxaldehyde. Blue and red series represent model and experimental values, respectively.
Figure 11. Inhibition of pig liver coumarin 7-hydroxylation by 1-benzothiophene-3-
ylmethylamine. Blue and red series represent model and experimental values, respectively.
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Figure 12. Inhibition of pig liver coumarin 7-hydroxylation by 1-benzothiophen-5-
carbaldehyde. Blue and red series represent model and experimental values, respectively.
Figure 13. Inhibition of pig liver coumarin 7-hydroxylation by 1-Benzothiophen-5-
ylmethylamine. Blue and red series represent model and experimental values, respectively
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Figure 14. Inhibition of pig liver coumarin 7-hydroxylation by 5-chloro-1-benzothio-3-
carbonitrile. Blue and red series represent model and experimental values, respectively.
3.3.2 Effect of coumarin concentration on IC50
To check the effect of substrate on the inhibitory potency of benzothiophene derivatives,
three most potent benzothiophene derivatives were tested at different concentrations of
coumarin. All samples were run in duplicate manner. Two different pig liver microsomes
were  used  to  get  results.  IC50 values were identified and calculated. Increase in IC50 values
with increasing substrate concentration (Table 4–6, fig. 15-17) showed competitive inhibition
manner of tested benzothiophene compounds, as the IC50 value increased linearly with
coumarin concentration. Thus tested inhibitors proved to be competitive inhibitor for
CYP2A19 catalyzed coumarin 7-hydroxylation of pig liver microsomes.
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Table 4. IC50 value of 1-benzothiophene-3-carbaldehyde at different coumarin
concentrations.
Pig # 4 Pig # 11
Coumarin conc.  [µM] IC50 [µM] Coumarin conc.  [µM] IC50 [µM]
6.25 2.56 3.125 0.88
12.5 3.01 6.25 2.0
25 3.65 12.5 2.1
50 4.30 25 2.4
100 7.60 100 5.7
y = 0,0519x + 2,2142
R² = 0,9788
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Figure 15 .The effect of coumarin on IC50 value of 1-benzothiophene-3-carbaldehyde
against pig liver coumarin 7-hydroxylation.
Table 5. IC50 value of 1-benzothiophen-3-ylmethylamine at different coumarin concentration.
Pig # 4 Pig # 11
Coumarin conc.  [µM] IC50 [µM] Coumarin conc.  [µM] IC50 [µM]
6.25 2.26 6.25 1.20
12.5 2.94 12.5 1.59
25 3.46 25 1.61
50 5.17 50 2.53
100 9.47 100 6.05
y = 0,0441x + 1,3209
R² = 0,9583
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Fig 16. The  effect  of  coumarin  on  IC50 value of I-benzothiophene-3-ylmethylamine against
pig liver coumarin 7-hydroxylation.
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Table 6. IC50 value of 1-benzothiophen-5-carbaldeyde at different coumarin concentration.
Pig # 4 Pig # 11
Coumarin conc.  [µM] IC50 [µM] Coumarin conc.  [µM] IC50 [µM]
- - 6.25 1.98
- - 12.5 3.1
25 6.09 25 3.3
50 9.46 50 4.42
100 20.18 100 12.42
       .
y = 0,1917x + 0,73
R² = 0,9895
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Figure 17. The effect of coumarin on IC50 value of 1-benzothiophene-5-carbaldehyde against
pig liver coumarin 7-hydroxylation.
3.3.3 Ki values
Ki values were calculated by the equation of Cheng and Prusoff (1973) and are listed in table
7.
Ki= IC50 / (1+[S/Km]) + E/2
Table 7. Ki values of tested chemical inhibitors (Benzothiophene derivatives)
Chemical inhibitor Ki (µM)
1-benzothiophene-3-carbaldehyde 2.21
I-benzothiophene-3-ylmethylamine 1.73
1-benzothiophene-5-carbaldehyde 0.91
y = 0,1066x + 0,9082
R² = 0,9295
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3.4 Discussion.
Coumarin a commonly used experimental prodrug is used widely to investigate the enzyme
activity in humans, mouse and pigs. In humans the 7-hydroxylation of coumarin is catalyzed
by human CYP2A6 (Rahnasto et al. 2011). Coumarin 7-hydroxylation activity has been
detected also in conventional pigs and mini pigs. In pigs coumarin 7-hydroxylation is
catalyzed by CYP2A19 (Skaanild & Friis 2005; Liu et al. 2011). Therefore coumarin 7-
hydroxylation activity and its inhibition reflects the catalytic capability of CYP2A19 enzyme
in pigs. Inhibition of individual pig CYP enzymes by selective chemical inhibitors is very
limited in pig liver microsomes. In the experimental part I examined the inhibition potency of
five chemical inhibitors (benzothiophe derivatives) to inhibit pig liver microsomes catalyzed
coumarin 7-hydroxylation. The main aim of the study was to find out the inhibition
interaction, mechanism and effect of substrate on inhibition of pig liver coumarin 7-
hydroxylation by five benzothiophene derivatives and to calculate their IC50 values. In
humans and pigs larger interindividual differences in coumarin hydroxylase activity have
been noted. For this reason the Vmax values for coumarin 7-hydroxylation could be different
in different samples of microsomes (Liu et al. 2011). In my experiment pig liver microsomes
were collected by three pig livers to ignore the inter-individual differences.
The IC50 values of tested inhibitory compounds (1-benzothiophen-3-carbaldeyde, 1-
benzothiophene-3-ylmethylamine, 1-benzothiophen-5-carbaldeyde, 1-benzothiophene-5-
ylmethylamine and 5-choro-1-benzothio-3-carbonitrile) for pig CYP2A19 catalyzed
coumarin 7-hydroxylation were calculated in my experiments and were as 2.4 µM, 2.6 µM,
5.3  µM,  42  µM and 50  µM,  respectively.  In  another  study  (Rahnasto  et  al.  2011)  all  these
compounds were tested against human CYP2A6 coumarin 7-hydroxylation and IC50 values
recorded were 1.6 µM, 1.5 µM, 0.9 µM, 1.7 µM and 41 µM respectively. The pig to human
IC50 ratio from both studies result  were calculated and are 1.5,  1.7,  5,  21 and 1.2 and result
showed that these chemical inhibitors are more potent for human CYP2A6. 1-benzothophene-
3-carbaldehyde, 1-benzothiophene-3-ylmethylamine and 5-chloro-1-benzothio-3-carbonitrile
showed quite similar inhibition potency against pig and human coumarin 7-hydroxylation in
mine and Rahnasto et al. 2011 experiments. The most potent inhibitory compound found in
my experiments was 1-benzothophene-3-carbaldehyde with IC50 value of 2.4 µM and 1-
benzothiophene-3-ylmethylamine with IC50 value of 2.6 against pig liver microsomes, these
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compound showed less inhibition potency toward pig CYP2A19 than human CYP2A6 and
are proved to be more potent inhibitor for human CYP2A6 and being proposed as lead
compound in the development of drugs in smoking reduction therapy (Rahnasto et al. 2011).
The inhibitory compound 1-benzothiophen-5-ylmethylamine (IC50 value  in  pigs  42  µM)
showed greater inhibition potency toward human CYP2A6 coumarin 7-hydroxylation. Larger
differences in inhibition potency of this compound was seen between human and pigs
coumarin 7-hydroxylation.
The compound which showed least inhibitory potency was 5-choloro-1-benzothio-3-
carbonitrile against pig and human coumarin 7-hydroxylation. 1-benzothiophen with methyl
amine at position 3 is much more potent than 1-benzothiophen with methyl amine at position
5. So as the methyl amine position shifted from position 3 to position 5, huge decrease in
inhibitory potency was seen in pig coumarin 7-hydroxylation reactions, but there is a little
difference in inhibition potency of these two compounds against human CYP2A6 (Rahnasto
et al. 2011). Carbaldehyde group at position 5 of 1-benzothiophene increases the inhibition
potency as compared to methyl amine at position 5 of same 1-benzothiophene.
Benzothiohene ring with carbaldehyde group on position 3 or on position 5 does not make a
big difference in inhibition potency of compound in both pigs and humans. Tested
benzothiophene derivatives showed competitive inhibition for the CYP2A19 of pig
microsomes. The Ki values were calculate for three most potent inhibitory compound’s (1-
benzothiophene-3-carbaldehyde, 1-benzothiophene-3-ylmethylamine and 1-benzothiophene-
5-carbaldehyde) and were 2.21 µM, 1.73 µM and 0.91 µM. The Ki values calculated in these
experiments could be used in elucidating the extent to which pig CYP2A contributes to the
metabolism of xenobiotics and new drugs by pig liver microsomes. The use of Ki in the
prediction of drug interactions for CYP inhibitors has been most frequent approach (Liu et al.
2011).
IC50 values of 1-benzothiophene-3-carbaldehyde. 1-benzothiophene-5-carbaldehyde and 1-
benzothiophene -3-ylmethylamine were below 10 µM. These derivatives were competitive
inhibitors for CYP2A19 mediated pig coumarin 7-hydroxylation. In same study (Rahnasto et
al. 2011) 1-benzothiophen-3-carbaldehyde, 1-benzothiophene-3-methylamine and 1-
benzothiophene-5-ylmethylamine were found to be most potent inhibitor of CYP2A6
coumarin 7-hydroxylation in humans. This show the binding affinity of inhibitors is affected
by electronic, hydrophobic and spatial properties of molecules. 1-benzothiophen-3-
carbaldehyde an inhibitor has thiophene and aldehyde functional group, each of this group
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has potential to inhibit CYP enzymes either irreversibly or become a more stable metabolite
by slow isomerization process. Formation of epoxide intermediate, which can attack the heme
or  nitrogen  atoms  in  the  side  chains  of  CYP,  appears  to  be  general  mechanism  behind  the
inhibitory properties of thiophene derivatives. On the other hand inactivation of CYP by
aldehydes functional group favours the formation of free radicals that can form heme adducts
and finally exert inhibition/ inactivation (Rahnasto et al 2011).
Knowledge about xenobiotic metabolizing enzyme provides ability to predict and understand
drug-drug interactions. Xenobiotic causing reversible or irreversible inactivation of drug
metabolizing enzymes causes increased exposure and bioavailability of other drugs. However
in-vitro inhibitory potencies of irreversible CYP inhibitors do not necessarily relative extents
of inhibition for in-vivo. Irreversible inhibition is of much importance in drug development
and discovery (Zhou & Zhou, 2009). Effect of CYP inhibition on xenobiotic
pharmacokinetics depends upon many factors like coadminintered drug, regimen, dose, other
inactivators with personal hepatic function and CYP genetics (Zhou & Zhou, 2009). Enzyme
inhibition a biological process is of much importance to know and describe the nature of
enzyme reaction, to check the effect of different parameters on the reaction rate and new
developments in medicinal and bioengineering industry. Main objective behind in-vitro
metabolic inhibition reactions is to prediction of in-vivo drug-drug interactions. In
conclusion, the above experiments show and describe the inhibition potency and mechanism
of inhibition of benzothiophene derivatives towards pig liver microsomal coumarin 7-
hydroxylase catalysed by CYP2A19. The result obtained in these experiments could be used
for QSAR modelling of CYP2A19. These benzothiophene derivatives showed similar or
greater inhibition potency towards human CYP2A6 mediated coumarin 7-hydroxylation
reported by Rahnasto et al. (2011).
This data could be base for further QSAR modelling and to predict the inhibition pattern of
xenobiotics in humans.
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